Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates. J of Skin. 2025;9(1):s519. doi:10.25251/skin.9.supp.519